Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Change to approval for medicinal cannabis

Change to approval for medicinal cannabis
8 February 2017


Patients seeking medicinal cannabis will no longer need the approval of a minister, but instead will go to the Ministry of Health.

Associate Health Minister Peter Dunne announced the change this morning, saying he was confident the ministry could take over now that firmer guidelines are in place for making decisions on the contentious issue.

The Science Media Centre asked experts for their reaction to the announcement. Feel free to use the comments below in your reports. Any further comments will be put on our website.

Professor Paul Smith, professor of neuropharmacology, University of Otago, comments:

"Overall, I think it is a positive step that brings New Zealand into line with many other countries such as the USA.

"However, it is important to be clear about what 'Cannabis-based medicine' (CBM) actually is. Cannabis the plant contains hundreds of chemicals and about 66 that are unique to the Cannabis plant.

"Therefore, CBM can potentially mean many things. Sativex [one of two pharmaceutical-grade cannabis-based products available here] contains equal concentrations of delta-9-THC, the main psychoactive ingredient of Cannabis, and cannabidiol (CBD), but other CBMs may contain different ratios or just CBD.

"Whatever the case, CBMs are not 'magic bullets'. The evidence that they work for some conditions like neuropathic pain is not entirely consistent or convincing, but they do appear to help some people. So, it is a question of benefit versus burden for a particular condition.

"In the case of terminal illness, there is not much reason to have concerns because the harm will be minimal and the patient may benefit.

"For non-terminal illness, one issue is the way it is taken. For example, Sativex is used as an oromucosal or oropharyngeal spray and this avoids the potential harm of smoking Cannabis, which is associated with damage to the lungs even if only Cannabis is used in the cigarettes (a point often overlooked in the medicinal Cannabis debate).

"According to current evidence, there are few long term risks from using drugs like Sativex. The doses of delta-THC are low and long-term studies indicate that it is well tolerated."

No conflicts of interest declared


ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Trade Plans: Prime Minister's Speech To International Business Forum

"The work to improve public services, build infrastructure, and solve social problems is possible only because we have enjoyed sustained, solid economic growth. A big reason for that is the Government’s consistent agenda of economic reform, and our determination to open up more opportunities for trade with the world." More>>

ALSO:

Media: TVNZ Flags Job Cuts To Arrest Profit Decline

Chief executive Kevin Kenrick said the changes were aimed at creating "a sustainable future video content business for TVNZ in an ever-changing media market." More>>

ALSO:

Reserve Bank: Wheeler Keeps OCR At 1.75%

Reserve Bank governor Graeme Wheeler kept the official cash rate unchanged at 1.75 percent, as expected, and reiterated his view that the benchmark rate doesn't need shifting for the foreseeable future. More>>

ALSO:

Retail: Pumpkin Patch Brand, IP Sold To Catch Group

The receivers of failed children's clothing retailer Pumpkin Patch have confirmed that the company's brand and intellectual property have been sold to Australian online retailer Catch Group. More>>

ALSO:

Oil: 2017 Block Offer Petroleum Tender Launched

New Zealand is well-placed to take advantage of the economic benefits of oil and gas exploration, Energy and Resources Minister Judith Collins announced today at the launch of the 2017 Block Offer petroleum tender. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news